Patents by Inventor Matthew K. Waldor

Matthew K. Waldor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Live attenuated cholera vaccine with probiotic properties
    Patent number: 11484585
    Abstract: Provided herein are genetically engineered Vibrio cholerae bacterial strains, compositions including the bacterial strains, and methods of using the same for the prevention of Vibrio cholerae infection in a subject.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 1, 2022
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Matthew K. Waldor, Troy Hubbard, Gabriel Billings
  • LIVE ATTENUATED CHOLERA VACCINE WITH PROBIOTIC PROPERTIES
    Publication number: 20200268868
    Abstract: Provided herein are genetically engineered Vibrio cholerae bacterial strains, compositions including the bacterial strains, and methods of using the same for the prevention of Vibrio cholerae infection in a subject.
    Type: Application
    Filed: July 12, 2018
    Publication date: August 27, 2020
    Inventors: Matthew K. Waldor, Troy Hubbard, Gabriel Billings
  • mutants and methods of use thereof
    Patent number: 8414903
    Abstract: The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such as enterohemorrhagic Escherichia coli.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: April 9, 2013
    Assignee: Tufts University
    Inventors: Matthew K. Waldor, Theresa D. Ho
  • LIVE BACTERIAL VACCINE SAFETY
    Publication number: 20130017218
    Abstract: The present invention provides for a method of reducing the reactogenicity of live attentuated bacterial vaccines by deleting at least a portion (e.g., the TLR-5 stimulating domain of a flagellin protein) of at least one of the bacterial genes that encodes a flagellin from the bacterium genome. These vaccines are directed against enteric or non-enteric flagellin-producing bacteria. A particular embodiment provides for a live attenuated cholera vaccine having reduced reactogenicity.
    Type: Application
    Filed: February 11, 2011
    Publication date: January 17, 2013
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Matthew K. Waldor
  • ESCHERICHIA COLI MUTANTS AND METHODS OF USE THEREOF
    Publication number: 20100092511
    Abstract: The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such as enterohemorrhagic Escherichia coli.
    Type: Application
    Filed: November 20, 2007
    Publication date: April 15, 2010
    Inventors: Matthew K. Waldor, Theresa D. Ho
  • Vibrionaceae replication factors and methods of use thereof
    Patent number: 7247437
    Abstract: The invention relates to compositions, methods and kits useful in modulating bacterial cell DNA replication and for treating pathogenic bacterial.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: July 24, 2007
    Assignee: Trustees of Tufts College
    Inventors: Matthew K. Waldor, Elizabeth S. Egan
  • Vibrio cholerae having increased sensitivity to antibiotics
    Patent number: 5945285
    Abstract: The invention provides bacterial strains with increased sensitivity to antibiotics and methods for making and using the strains.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: August 31, 1999
    Assignee: President and Fellows of Harvard College
    Inventors: John J. Mekalanos, Matthew K. Waldor
  • Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
    Patent number: 4695459
    Abstract: Certain autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus may be prevented or attenuated by in vivo treatment with a complement-fixing anti-Leu3 (CD4) antibody that is cytotoxic to Leu3 (CD4) phenotype T cells.
    Type: Grant
    Filed: December 26, 1984
    Date of Patent: September 22, 1987
    Assignee: The Board of Trustees of Leland Stanford Junior University
    Inventors: Lawrence Steinman, Matthew K. Waldor, Subramanian Sriram, Leonard A. Herzenberg, Leonore A. Herzenberg